🚀 VC round data is live in beta, check it out!
Eli Lilly Valuation Multiples
Discover revenue and EBITDA valuation multiples for Eli Lilly and similar public comparables like Johnson & Johnson, AbbVie, Roche, AstraZeneca and more.
Eli Lilly Overview
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Founded
1901
HQ
Employees
50.0K
Website
Sectors
Financials (LTM)
EV
$863B
Eli Lilly Financials
Eli Lilly reported last 12-month revenue of $70B and EBITDA of $33B.
In the same LTM period, Eli Lilly generated $59B in gross profit, $33B in EBITDA, and $24B in net income.
Revenue (LTM)
Eli Lilly P&L
In the most recent fiscal year, Eli Lilly reported revenue of $65B and EBITDA of $32B.
Eli Lilly expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $70B | XXX | $65B | XXX | XXX | XXX |
| Gross Profit | $59B | XXX | $54B | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | $33B | XXX | $32B | XXX | XXX | XXX |
| EBITDA Margin | 47% | XXX | 49% | XXX | XXX | XXX |
| EBIT Margin | 44% | XXX | 46% | XXX | XXX | XXX |
| Net Profit | $24B | XXX | $22B | XXX | XXX | XXX |
| Net Margin | 35% | XXX | 33% | XXX | XXX | XXX |
| Net Debt | — | — | $35B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Eli Lilly Stock Performance
Eli Lilly has current market cap of $828B, and enterprise value of $863B.
Market Cap Evolution
Eli Lilly's stock price is $927.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $863B | $828B | 0.0% | XXX | XXX | XXX | $24.37 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEli Lilly Valuation Multiples
Eli Lilly trades at 12.3x EV/Revenue multiple, and 26.4x EV/EBITDA.
EV / Revenue (LTM)
Eli Lilly Financial Valuation Multiples
As of April 19, 2026, Eli Lilly has market cap of $828B and EV of $863B.
Equity research analysts estimate Eli Lilly's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eli Lilly has a P/E ratio of 33.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $828B | XXX | $828B | XXX | XXX | XXX |
| EV (current) | $863B | XXX | $863B | XXX | XXX | XXX |
| EV/Revenue | 12.3x | XXX | 13.2x | XXX | XXX | XXX |
| EV/EBITDA | 26.4x | XXX | 27.2x | XXX | XXX | XXX |
| EV/EBIT | 28.1x | XXX | 29.1x | XXX | XXX | XXX |
| EV/Gross Profit | 14.7x | XXX | 16.0x | XXX | XXX | XXX |
| P/E | 33.9x | XXX | 38.0x | XXX | XXX | XXX |
| EV/FCF | 59.6x | XXX | 78.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Eli Lilly Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Eli Lilly Margins & Growth Rates
Eli Lilly's revenue in the last 12 month grew by 22%.
Eli Lilly's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.5M for the same period.
Eli Lilly's rule of 40 is 75% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Eli Lilly's rule of X is 114% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Eli Lilly Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 47% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | 29% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 75% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 114% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 17% | XXX | 17% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 20% | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Eli Lilly Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Eli Lilly | XXX | XXX | XXX | XXX | XXX | XXX |
| Johnson & Johnson | XXX | XXX | XXX | XXX | XXX | XXX |
| AbbVie | XXX | XXX | XXX | XXX | XXX | XXX |
| Roche | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca | XXX | XXX | XXX | XXX | XXX | XXX |
| Merck | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eli Lilly M&A Activity
Eli Lilly acquired XXX companies to date.
Last acquisition by Eli Lilly was on XXXXXXXX, XXXXX. Eli Lilly acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Eli Lilly
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEli Lilly Investment Activity
Eli Lilly invested in XXX companies to date.
Eli Lilly made its latest investment on XXXXXXXX, XXXXX. Eli Lilly invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Eli Lilly
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Eli Lilly
| When was Eli Lilly founded? | Eli Lilly was founded in 1901. |
| Where is Eli Lilly headquartered? | Eli Lilly is headquartered in United States. |
| How many employees does Eli Lilly have? | As of today, Eli Lilly has over 50K employees. |
| Who is the CEO of Eli Lilly? | Eli Lilly's CEO is David A. Ricks. |
| Is Eli Lilly publicly listed? | Yes, Eli Lilly is a public company listed on NYSE. |
| What is the stock symbol of Eli Lilly? | Eli Lilly trades under LLY ticker. |
| When did Eli Lilly go public? | Eli Lilly went public in 1970. |
| Who are competitors of Eli Lilly? | Eli Lilly main competitors are Johnson & Johnson, AbbVie, Roche, AstraZeneca. |
| What is the current market cap of Eli Lilly? | Eli Lilly's current market cap is $828B. |
| What is the current revenue of Eli Lilly? | Eli Lilly's last 12 months revenue is $70B. |
| What is the current revenue growth of Eli Lilly? | Eli Lilly revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Eli Lilly? | Current revenue multiple of Eli Lilly is 12.3x. |
| Is Eli Lilly profitable? | Yes, Eli Lilly is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Eli Lilly? | Eli Lilly's last 12 months EBITDA is $33B. |
| What is Eli Lilly's EBITDA margin? | Eli Lilly's last 12 months EBITDA margin is 47%. |
| What is the current EV/EBITDA multiple of Eli Lilly? | Current EBITDA multiple of Eli Lilly is 26.4x. |
| What is the current FCF of Eli Lilly? | Eli Lilly's last 12 months FCF is $14B. |
| What is Eli Lilly's FCF margin? | Eli Lilly's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Eli Lilly? | Current FCF multiple of Eli Lilly is 59.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.